SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / The latest iteration of the innovative Gambit Series of unmanned combat air vehicles (UCAV) from General Atomics Aeronautical Systems, Inc. (GA-ASI) is Gambit 6, a collaborative combat aircraft (CCA) that adds air-to-ground operations to its already proven air-to-air capability. The multi-role platform is optimized for roles such as electronic warfare, suppression of enemy air defenses (SEAD), and deep precision strike, making it a versatile option for evolving defense needs.
Air forces throughout the world are looking to air-to-ground-capable CCAs to enhance operational capabilities and address emerging threats in a denied environment. Gambit 6 is being developed to meet the corresponding need for adaptability, scalability, and mission-specific performance.
“These are real threats, and they require real solutions,” said GA-ASI President David R. Alexander. “The modular architecture and signature-reducing internal weapons bay of Gambit 6 allow for easy integration of advanced autonomy, sensors, and weapons systems, ensuring the aircraft can adapt to a wide range of operational scenarios.”
Airframes will be available for international procurement starting in 2027, with European missionized versions deliverable in 2029. GA-ASI is building industry partnerships throughout Europe with the aim of providing sovereign capabilities for all its platforms.
GA-ASI’s Gambit Series envisions multiple CCA variants rapidly reconfigured from a common core, enabling substantial commonality for rapid and affordable production at scale.
The Gambit Series is a modular family of unmanned aircraft designed to meet diverse mission requirements, including intelligence, surveillance, and reconnaissance; multi-domain combat; advanced training; and stealth reconnaissance. It’s built around a common core platform that accounts for a significant proportion of the aircraft’s hardware, including the landing gear, baseline avionics, and chassis. This shared foundation reduces costs, increases interoperability, and accelerates the development of mission-specific variants like Gambit 6.
By leveraging specialized configurations and advanced autonomy, Gambit aircraft offer tailored capabilities that enhance operational efficiency, reduce costs, and improve survivability in contested environments. One Gambit derivative is the U.S. Air Force’s YFQ-42A, developed as part of that service’s effort to field an AI-enabled uncrewed wingman. Based off the original Gambit 2 concept, the YFQ-42A is designed to complement human-crewed fighters like the F-35 and Next-Generation Air Dominance (NGAD) systems, expanding sensing, weapons capacity, and survivability in contested airspace.
The original concept for Gambit was announced three years ago and was based on four models. Gambit 1 is a nimble sensing platform optimized for long endurance; Gambit 2 adds the provision for air-to-air weapons; Gambit 3 looks much like Gambit 2 but is optimized for a complex adversary air role; Gambit 4 is a combat reconnaissance-focused model with no tail and swept wings. Then in 2024, GA-ASI announced Gambit 5 for ship-based CCA operations.
About GA-ASI
General Atomics Aeronautical Systems, Inc., is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.
Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.
LOS ANGELES, CA / ACCESS Newswire / November 4, 2025 / Introducing Beleve Vision, a revolutionary immersive-technology company borne from Japan’s cutting-edge research, poised to change the way we see and interact with digital content. At its core is the patented “Portalgraph™” display system – a true game-changer that turns flat screens into fully immersive, 3-dimensional holographic experiences.
A Japanese Innovation Goes Global Originating in Japan, Beleve Vision’s R&D team has engineered Portalgraph™ to blur the lines between physical and digital worlds. No heavy headsets. No bulky gear. Just groundbreaking tech that transforms any compatible screen into a live, interactive 3D hologram.
How it Works Portalgraph’s system utilizes perspective-tracking, advanced rendering, and proprietary display hardware so that digital content appears to float and shift in real space based on the viewer’s vantage point. The result: immersive depth, natural movement, and collective shared experiences – all accessible without goggles or isolated head-mounted displays.
Why This Matters
Current flat screens limit immersion; we’re stuck looking at content instead of in it.
Virtual-reality headsets may deliver immersion but at the cost of comfort, accessibility, and social interaction. Portalgraph™ addresses those constraints.
The global immersive-tech market is projected to reach extraordinary valuations in the coming years – positioning Beleve Vision at the forefront of a high-growth sector.
Crowdfunding Opportunity – Invest Early Beleve Vision is now open for early-stage investment through a Regulation CF offering via the PicMii Crowdfunding Portal. https://www.picmiicrowdfunding.com/deal/Beleve%20Vision/ This is a rare chance to become part of a technology that could redefine digital display, entertainment, gaming, retail, education and beyond.
Why Invest Now
Be part of a disruptive hardware-software platform crossing from flat screens into spatial, holographic display.
Developed by a team steeped in Japanese design, engineering and immersive-media pedigree.
Positioned for multi-industry application: entertainment, museums, retail, remote collaboration, training, and more.
Early investment provides potential upside in the rapidly growing spatial computing and immersive display market.
For press enquiries, interviews, or more information about the crowdfunding offering, please contact:
As one of the leading voices on responsible AI, Gonzalez will join two high profile sessions to discuss the pros and cons of near-term vs. long-term AI investment and the realities of deploying enterprise AI ethically and sustainably.
LISBON, PORTUGAL / ACCESS Newswire / November 4, 2025 / Sama, delivering data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services, today announced that CEO Wendy Gonzalez will speak in two separate sessions at the upcoming Web Summit, taking place in Lisbon, Portugal, on November 12-13, 2025.
The first session, entitled China’s AI Playbook, will examine China’s focus on immediate, practical applications of existing AI technologies – from automated manufacturing to healthcare and logistics – versus Silicon Valley’s heavy investment in the long-term pursuit of artificial general intelligence. As concerns about an AI investment bubble intensify, Wendy will be joined by Jostein Hague, political economist at Cambridge University and Gabrielle Lawrence, features writer of CGTN Europe, to explore whether Beijing’s approach of emphasizing near-term economic value offers a more sustainable path forward for the industry. The discussion takes place on Wednesday, November 12, at 15:55 on the Economic Policy Summit stage.
Gonzalez will also participate in the Demystifying Responsible AI: A Guide for Leaders session, taking place Thursday, November 13 at 10:35 am on the Government Summit stage. Alongside Angeli Patel, executive director of the Berkeley Center for Law and Business and Shelley McKinley, chief legal officer at GitHub, she will discuss the challenges, opportunities, regulatory considerations and strategies necessary to successfully deploy responsible AI and manage risk, as well as practical steps to ensure compliance and business success.
“We’re at an interesting inflection point in AI. Silicon Valley continues to push the boundaries of AGI, while China demonstrates the power of practical, revenue-generating applications,” said Gonzalez. “The real question, however, is whether we’re building systems that are sustainable, responsible and beneficial for everyone. These aren’t abstract debates anymore – companies are making billion-dollar bets. Web Summit is the perfect venue to discuss how to build AI the right way from the start.”
In addition to her mainstage appearances, Gonzalez has been invited to moderate a private roundtable during the Web Summit EcoSystem Summit Offsite, an exclusive, invite-only event on Monday, November 10. The gathering will convene 150 policymakers, government officials and tech leaders to discuss strategies for building thriving, sustainable technology ecosystems around the world.
A certified B Corp, Sama is committed to leading the industry in responsible AI, prioritizing compliance with critical AI legislation around the world. The company’s impact mission has resulted in lifting over 68,000 individuals out of poverty, and its most recent Impact Report details significant strides toward its sustainability goals, including efforts to become net zero by 2050 and its role in the United Nations Global Compact (UNGC), the world’s largest voluntary corporate sustainability initiative.
Web Summit is one of the world’s largest technology conferences, bringing together over 70,000 attendees from more than 150 countries. This year’s conference will feature discussions on AI and emerging technology, and their impact on business, government and society. More information is available at https://websummit.com.
About Sama Sama delivers data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services. By combining advanced platforms with expert human judgment, Sama helps some of the world’s largest companies, including 30% of the Fortune 50, move AI models from development to production with confidence. With thousands of skilled data professionals and industry-leading quality guarantees, Sama tackles the critical challenge that over 63% of AI models fail to reach production due to poor data quality.
Founded in 2008, Sama has delivered more than 40 billion data points and created employment opportunities that have helped over 70,000 people lift themselves out of poverty. As a certified B Corporation, Sama is committed to advancing both technological innovation and social impact. Learn more at www.sama.com.
Dr. Kurt A. Dasse Unveils His Gripping Works of Fiction Exploring Love, Law, and Resilience
COCOA BEACH, FL / ACCESS Newswire / November 3, 2025 / Readers seeking moving, intelligent, and emotionally gripping fiction will find compelling new works by Dr. Kurt A. Dasse, whose unique background in medical science informs each narrative with depth, realism, and heart.
His books, Law and the Heart and The Sleep Doctors, each stand on their own yet collectively highlight his ability to blend storytelling with critical human themes that resonate with women and readers worldwide.
Law and the Heart combines romance, legal suspense, and medical drama. The story follows Dr. Nathaniel Belder, a world-renowned heart surgeon, and Sandra, a brilliant Singaporean attorney. Their budding love story becomes entangled in a murder mystery tied to medical malpractice, device innovation, and hidden conspiracies; testing both their personal bond and professional courage.
Meanwhile, The Sleep Doctors takes readers deep into a techno-thriller rooted in neuroscience and military science. It follows the visionary Dr. David Brace, whose research into brainwave technology and sleep manipulation opens doors to innovation but also peril when his work is co-opted for dangerous purposes. This narrative blends science, suspense, and romance, exploring the fine line between genius and obsession.
Across both novels, Dr. Dasse delivers fiction that is both thought-provoking and emotionally accessible, offering stories that are page-turners while also reflecting on universal struggles: love, loss, resilience, and the quest for truth. His works are especially relevant for women readers who appreciate strong emotional arcs and authentic human challenges intertwined with science and law.
“Fiction allows me to explore truths about medicine, ethics, and human resilience in ways that research articles never could,” Dr. Dasse notes. “Each story is rooted in what I’ve witnessed over decades in medical science but transformed into narratives that readers can connect with on a deeply personal level.”
About the Author
Dr. Kurt A. Dasse is an internationally recognized physiologist with over forty years of experience developing and commercializing medical devices and therapies for cardiac, respiratory, and kidney disorders. A Clinical Professor of Cardiothoracic Surgery at the University of Louisville Medical School, he has authored more than 100 journal articles and book chapters. Today, he brings his expertise to fiction writing, crafting novels that merge medical authenticity with compelling human stories.
Availability
Law and the Heart and The Sleep Doctors are available nationally and internationally. Readers, bloggers, and media outlets are encouraged to explore these works that illuminate the human spirit through medical and legal storytelling.
For more information or interview requests, please contact:
These titles not only entertain but also invite readers to reflect on the intersections of medicine, morality, and love; an exploration that speaks to the resilience of the human heart in every sense.
Disclaimer: This press release has been prepared by Ingram Publisher’s House for media distribution. The views and opinions expressed herein are those of the author and do not necessarily reflect those of Ingram Publisher’s House. For editorial or interview inquiries, please contact Ingram Publisher’s House at larry.white@ingrampublishershouse.com
BANFF, ALBERTA / ACCESS Newswire / November 3, 2025 / Banff Sunshine Village officially opened yesterday morning, Sunday, November 2, making it the first ski resort in Canada to welcome skiers and riders for the 2025/26 winter season. This potentially marks the earliest opening in the resort’s 98-year history. This year’s opening for Banff Sunshine Village is about a week earlier than both their anticipated opening day and last season’s opening day.
On Sunday, guests were encouraged to hit the slopes dressed in their Halloween costume. Strawberry Express and the Learning Area opened for skiers and snowboarders. All terrain of Strawberry Express is open, including the 7-feature terrain park with two jib lines – one small and one medium.
“It is so exciting to be the first ski resort in the country to open for the season,” shares Kendra Scurfield, VP of Communications at Banff Sunshine Village. “This is the earliest opening in our corporate memory – We are thrilled to welcome back skiers and snowboarders for another incredible season at Sunshine!”
To celebrate the early opening, Banff Sunshine Village invited guests to show their love for the Blue Jays by wearing a jersey or celebrating the spooky season with a Halloween costume. The Banff Sunshine Village team was onsite handing out $10 vouchers to those in costume or showing their Jays’ spirit. Over 100 vouchers were given away to happy skiers and snowboarders.
Located in Banff National Park, Banff Sunshine Village is known for having one of North America’s longest ski season. Just last week, Banff Sunshine was named SKI magazine’s Top 30 Resorts in the West and number 2 overall in the magazine prestigious reader’s poll for the second year in a roll. The resort features over 3,300 acres of skiable terrain spread across three mountains and 137 runs, featuring what is often called Canada’s Best Snow.
Early season ticket pricing is in effect until the resort opens more fully. Information on terrain and mountain updates can be found on the resort’s Instagram (@sunshinevillage) and Facebook (Banff Sunshine Village). A proud member of both Mountain Collective Pass and IKON Pass, for more details on Banff Sunshine Village, its offerings and how to purchase a lift ticket or a season pass, visit skibanff.com.
###
About Banff Sunshine Village:
Perched at 7,000 feet (2,133 meters) above sea level, Banff Sunshine Village is nestled in the heart of the Canadian Rockies in Banff National Park. Renowned for its all-natural snow, this world-class resort attracts skiers and snowboarders from around the globe during its impressive seven-month winter season, running from mid-November to late May. Come late June, the landscape transforms as summer arrives at Banff Sunshine Meadows, where Alberta’s native wildflowers blanket hundreds of pristine, protected alpine acres in a vibrant display of color. From carving turns on Canada’s Best Snow in the winter to hiking through breathtaking mountain meadows in the summer, Banff Sunshine offers an unparalleled year-round escape for nature lovers and outdoor enthusiasts alike.
For press inquiries, please contact:
Contact Information
Kendra Scurfield VP of Marketing, Brand and Communications kscurfield@skibanff.com +1-403-830-7946
GA-ASI Brings Uncrewed Fighter Fleet into Focus at International Fighter Conference 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 3, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in uncrewed aircraft systems, is excited to participate in the upcoming 25th anniversary of the International Fighter Conference as the event’s only Four-Star Lead Partner, reflecting the company’s global commitment to the future of autonomous fighter jets.
GA-ASI’s growing production fleet of unmanned combat jets – including the MQ-20 Avenger®, XQ-67A Off-Board Sensing Station, and YFQ-42A Collaborative Combat Aircraft – is defining the global future of autonomous and semi-autonomous combat jets, leading the way in autonomy development, manned-unmanned teaming, and affordable, rapid delivery at scale. The company’s vision for its Gambit Series of modular, scalable, uncrewed fighters paves the way for U.S. forces, allies and partners to quickly evolve global air forces for the future fight.
Publicly promising to build and fly a production-representative uncrewed jet fighter for the U.S. Air Force by summer 2025, GA-ASI launched its YFQ-42A CCA in August, pioneering a new era for fighter jets. Flight operations continue today across the growing fleet, cementing GA-ASI’s continued dominance in UAS development and delivery while meeting anticipated timelines and remaining true to its word.
“The YFQ-42A is a revolutionary aircraft, and the fleet is in production and in the air today,” said David R. Alexander, president of GA-ASI. “This isn’t a ‘wait and see’ moment. We’re flying. We’re delivering. And we’re advancing this future of combat aviation, the same way we have for more than three decades.”
Since 1992, GA-ASI has delivered more than 1,300 combat aircraft to U.S. forces and international partners, surpassing more than 9 million total flight hours in 2025. The company’s Predator®, Reaper®, Gray Eagle®, SkyGuardian® and SeaGuardian® aircraft continue to set the standard for medium-altitude, long-endurance UAS performance.
The company’s MQ-20 Avenger, an internally funded uncrewed combat jet that achieved first flight in 2009, continues to serve as a test bed for advanced autonomy integration and demonstration, incorporating and flying the latest cutting-edge software from U.S. government sources, leading industry suppliers and GA-ASI’s own autonomy software development teams, often at company expense.
For International Fighter Conference, Nov. 4-6 in Rome, GA-ASI plans to offer attendees a chance to see the future for themselves, with a full-scale model display of the YFQ-42A CCA co-located inside the show venue and other announcements. For more information on IFC 2025, visit https://www.defenceiq.com/events-internationalfighter.
About GA-ASI General Atomics Aeronautical Systems, Inc., is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.
Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.
Designed for business owners and accountants juggling multiple deadlines, Auto Payroll handles recurring pay runs automatically, accurately, and on schedule.
CANTON, OH / ACCESS Newswire / November 4, 2025 / Patriot Software, a leading provider of accounting and payroll software in the USA, today announced Auto Payroll, a powerful new feature designed to eliminate repetitive administrative work for small business owners and accountants. The feature is available immediately to both Full Service Payroll and Basic Payroll customers.
Auto Payroll is engineered for companies with predictable payrolls, where employees and pay amounts remain consistent each run. By fully automating these recurring pay runs, Patriot empowers business owners to eliminate tedious re-entry and oversight tasks, saving time, reducing human error, and keeping operations running effortlessly.
Payroll is essential, yet it consistently ranks as one of the biggest time drains for small business owners. A recent survey found that owners spend an average of five hours every single pay period preparing and processing payroll. Although customers already average minutes with Patriot Payroll®, Auto Payroll eliminates the need to log in entirely, saving business owners with routine, unchanging payrolls even more precious time.
“This feature saves employers valuable time,” said Mary Rolfes, Payroll Product Manager at Patriot Software. “Our customers already appreciate how simple payroll is with Patriot. Auto Payroll takes that simplicity a step further, eliminating extra steps for those who pay the same employees the same amount each period. It’s designed for busy owners and accountants who need to streamline their work without sacrificing accuracy.”
Built with flexibility and precision at its core, Auto Payroll supports both salaried and hourly employees, with or without direct deposit. Crucially, employers still receive an advance notification before each scheduled run is processed, providing a final window of time to easily stop the payroll if needed before the system executes the run.
American business owners wanting to take advantage of Patriot Software’s automated payroll as well as other time saving features, can sign up on Patriot’s website, www.patriotsoftware.com, for a 30-day free trial. Following the trial, new customers can enjoy 50% off for the next three months.
Patriot Software is disrupting the accounting and payroll industries with its low prices, achieving the 100th percentile for customer loyalty and satisfaction, and award-winning software. Patriot offers cloud-based accounting, payroll, HR, and time and attendance software solutions that help American businesses with up to 500 employees simplify their administrative tasks. Patriot’s US-based customer support team provides a personal touch that most software companies lack today. The company has been serving tens of thousands of businesses nationwide since 2002.
The World’s Elite Koi Breeders, Judges, and Hobbyist Converge in Las Vegas for the Ultimate Global Competition in Art, Innovation, and Aquaculture.
LAS VEGAS, NEVADA / ACCESS Newswire / November 4, 2025 / Las Vegas will shimmer with color, culture, and creativity as the All American Koi Show 2026 (AAKS) returns – bigger, BOLDER, and more internationally connected than ever before. The three-day event celebrates the artistry of koi fish and the powerful intersection of tradition, entrepreneurship, competition, and entertainment.
All American Koi Show 2026 Las Vegas International koi breeders and enthusiasts gathered for the All-American Koi Show 2026 in Las Vegas, USA.
AAKS 2026 will unite world-renowned Japanese judges, business pioneers, and global enthusiasts in one unforgettable weekend experience. From hands-on pond-building apprenticeships to an exclusive banquet and celebrity-filled after-parties, the event is designed to engage every sense and every level of passion for koi culture.
“AAKS isn’t just about competition – it’s about connection,” says Hector Mardueno, founder of W. Lim Corporation & the All American Koi Show. “We’re blending East and West, legacy and innovation, business and art, all through the koi’s timeless symbolism of perseverance and beauty.”
The event will feature eight integrated experiences, each highlighting a distinct side of the global koi movement:
Each experience flows into one shared mission – to elevate koi culture to a global art form and create new bridges between innovation, entrepreneurship, and tradition.
AAKS 2026 is expected to draw guests from across the America’s, All Asia, and Europe, attracting luxury sponsors, global media, and collectors worldwide.
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Monday, November 3rd, at 09:45am ET at the Spartan Capital Investor Conference 2025 in New York City.
Event Information:
Event
NanoViricides Presentation at the Spartan Capital Investor Conference – 2025, New York, NY
Track
2
Date
Monday, November 3, 2025
Time
09:45am
Location
Marriott Marquis Hotel, New York, NY
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
NanoViricides’ Current Antiviral Drugs Pipeline: NV-387, A Revolutionary Broad-Spectrum Antiviral with Multiple Indications
The Phase II clinical stage revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections. Over 90% of human pathogenic viruses use heparan sulfate features, which NV-387 copies and presents to fool the virus.
NV-387 is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle using the same features that the virus uses to infect cells.
Viruses cannot escape NV-387 despite all the changes in the field because the virus still needs to bind to heparan-sulfate like features in order to cause productive pathogenic infection. NV-387 presents copious amounts of these binding sites to the virus, thereby engulfing the virus particle. Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates.
This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
NV-387 stands to combat viral infections where there is no current medical treatment available, including RSV for pediatrics, Measles, MPox, and others.
NanoViricides lead clinical stage drug candidate NV-387 is rapidly moving into Phase II clinical trial for the treatment of MPox in the Democratic Republic of Congo.
Additionally, NV-387 was found to be substantially superior to Tamiflu as well as Xofluza against Influenza virus in animal model studies [1].
Should Bird Flu H5N1 turn into a human outbreak, variants resistance to Tamiflu and Xofluza can be expected to generate rapidly [2]. NV-387 would be the ideal drug to combat the resulting outbreak, epidemic or pandemic. The causative influenza virus would not be able to escape NV-387 [3].
A separate Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI) is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease.
NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections.
There is no treatment approved for RSV, an important disease for infants and children in early life, as well as for geriatric subjects.
NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
There is no treatment approved for MPox; tecovirimat (TPOXX) has failed clinical trials, and no results are available from the brincidofovir (TEMBEXA) clinical trial “MOSA”.
“For Smallpox bio-threat readiness, the USA remains without an effective drug because of deficiencies in the two drugs approved under animal rule [4],” asserted Anil Diwan, PhD, President of the Company, adding, “NV-387 is ready to fill this gap.”
US government acquisitions for smallpox drugs have been in the range of hundreds of millions of dollars.
Additionally, NV-387 has shown excellent effectiveness against Measles virus lethal lung infection in a humanized (hCD150+ knock-in) mouse model.
There is no treatment approved for Measles. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
NanoViricides’ Robust Technology Platform Has Enabled a Broad Drugs Pipeline: HerpesViruses, HIV, Others
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
In addition to NV-387, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
The Spartan Capital Investor Conference is a premier event that brings together public company executive teams, institutional investors, thought leaders in the U.S. capital markets, and representatives from Spartan Capital. This conference offers a unique opportunity for networking, knowledge sharing, and strategic discussions.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
[1] Tamiflu (Oseltamivir) – Roche. Xofluza (Baloxavir) – Shionogi, Roche. H5N1 bird flu viruses resistant to Oseltamivir have already occurred. Resistance to Xofluza occurred at a high frequency in its clinical trial.
[2] Influenza viruses generate variants by more mechanisms than most viruses: (a) by mutations, typically few and small changes in viral proteins; (b) by recombinations, wherein portions of its genomic strands are swapped between the strands derived from two different Influenza A viruses infecting the same cell; (c) by re-assortments, wherein entire genomic segment from one Influenza A virus is packaged into a different Influenza A virus in the same cell. Each complete Influenza A virus contains eight separate genomic RNA strands, giving it tremendous flexibility for “swapping” these segments and generating new variants. It is thought that all influenza A viruses causing outbreaks or pandemics among humans since the 1900s originated from strains circulating in wild aquatic birds through reassortment with other influenza strains (wikipedia, https://en.wikipedia.org/wiki/Influenza_A_virus).
[3] All Influenza viruses bind to HSPG (heparan sulfate proteoglycan) as the first “attachment receptor”, and thus are targeted by the drug NV-387. The viruses then gain proximity to cells, and latch onto the Sialylated glycoproteins on the cell surface which is called the “cognate receptor” that enables the virus to be taken inside the cell. The cognate receptor for Influenza viruses that remain infectious to birds is slightly different from the one that the virus would need to use for efficiently infecting human cells. However, just one or a few mutations would be required in the currently circulating H5N1 bird flu viruses to become efficient in human-to-human transmission. Two different clades of H5N1 are circulating, one in wild birds, infecting into poultry, and another in dairy cattle, infecting pets and animals that drink raw milk, bringing the threat closer to a potential pandemic than it has ever been since the late 1990s.
[4] Tecovirimat (TPOXX) was approved under the US FDA Animal Rule, and is stockpiled by the US Government Strategic National Stockpile (SNS). However, Tecovirimat-resistant viruses develop with a single point mutation in the viral VP37 protein. It is illogical to believe that any terrorist attack would be from a non-resistant smallpox strain. Brincidofovir (Tembexa) was approved under the US FDA Animal Rule, and is stockpiled in SNS. Brincidofovir carries a black box warning due to increased mortality rates in another indication, causes elevation of liver damage-related markers, is a carcinogen, may cause embryonic or fetal harm, and may irreversibly impair fertility, according to its prescribing information, limiting its applicability as a drug to be used across all population in the case of a smallpox bio-terrorism event (https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf.).
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESS Newswire / November 3, 2025 / American Critical Minerals Corp. (“American Critical Minerals” or the “Company“) (CSE:KCLI)(OTCQB:APCOF)(FRANKFURT:2P30) is pleased to announce that it has closed its previously announced “bought deal” offering, pursuant to which the Company issued 15,574,450 units of the Company (the “Units“) at a price of $0.35 per Unit (the “Offering Price“) for aggregate gross proceeds to the Company of approximately $5,451,000, including the exercise in full of the Underwriter’s option (the “Brokered Offering“).
Research Capital Corporation (the “Underwriter“) acted as the sole underwriter and sole bookrunner under the Brokered Offering.
The Company is also pleased to announce that it has closed its previously announced concurrent non-brokered private placement, pursuant to which the Company issued 5,714,286 Units at the Offering Price for aggregate gross proceeds to the Company of $2,000,000.10 (the “Non-Brokered Offering” and together with the Brokered Offering, the “Offering“). Together, the Company raised aggregate gross proceeds of approximately $7,451,000 under the Offering.
Simon Clarke, President and CEO stated, “we are very pleased with the level of support that we received for this financing. The Company is now funded to commence confirmation and resource drilling at its Green River Project which is a major milestone for the Company. The location of the project, close to existing potash production and contiguous with advanced lithium development, combined with historic data from numerous oil and gas wells, provides us with a high level of confidence as to the potential of the project. We are now in position to implement the steps needed to confirm that data with the goal of converting our exploration targets to maiden resources for potash, lithium and bromine and to take the project to the next level.”
Each Unit is comprised of one common share of the Company (a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.45 per Common Share for a period of 36 months following closing of the Offering, provided that holders will not be permitted to exercise Warrants until 60 days following closing of the Offering.
The net proceeds from the Offering of the Units will be used to launch an initial drill program targeting potash, lithium and bromine at the Company’s Green River Project, focused on confirming and updating historic drill data, and for working capital and general corporate purposes.
The Units issued under the Offering were offered for sale pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by CSA Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (collectively, the “Listed Issuer Financing Exemption“), in all provinces of Canada, except Quebec, and other qualifying jurisdictions, including the United States. The Units offered under the Listed Issuer Financing Exemption will be immediately “free-trading” under applicable Canadian securities laws.
The Company entered into an underwriting agreement dated November 3, 2025, with the Underwriter, pursuant to which the Company paid the Underwriter a cash commission of 7.0% of the aggregate gross proceeds of the Brokered Offering and such number of non-transferable broker warrants (the “Broker Warrants“) as is equal to 7.0% of the number of Units sold under the Brokered Offering. Each Broker Warrant entitles the holder to purchase one Unit at an exercise price equal to the Offering Price for a period of 36 months following the Closing.
In connection with the Non-Brokered Offering, the Company paid an aggregate cash finder’s fee of $137,882.50 and issued 393,950 Broker Warrants to such finders. The Broker Warrants are subject to a statutory hold period of four months and a day from the closing of the Offering.
Dean Besserer, COO and Director (the “Insider“), participated in the Non-Brokered Offering purchasing 50,000 Units at the Offering Price for gross proceeds of $17,500.00. Participation by the Insider in the Non-Brokered Offering was considered a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“) as the Insider is a director and senior officer of the Company. Pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company is exempt from obtaining a formal valuation and minority approval of the Company’s shareholders in respect of the Insider participation due the fair market value of the Insider participation being below 25% of the Company’s market capitalization for the purposes of MI 61-101. The Company will file a material change report in respect of closing of the Offering. However, the material change report will be filed less than 21 days prior to the closing of the Offering, which is consistent with market practice and the Company deems reasonable in the circumstances.
This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.
About American Critical Minerals’ Green River Potash and Lithium Project
The Green River Potash and Lithium Project is situated within Utah’s highly productive Paradox Basin, located 20 miles northwest of Moab, Utah. It has significant logistical advantages including close proximity to major rail hubs, airport, roads, water, towns and labour markets. It also benefits from close proximity to the agricultural and industrial heartland of America and numerous potential end-users for its products.
The history of oil and gas production across the Paradox Basin provides geologic data from historic wells across the Project, and the wider Basin, validating and de-risking the potential for high grade potash and large amounts of contained lithium. Wells in and around the project reported lithium up to 500 ppm, bromine up to 6,100 ppm and boron up to 1,260 ppm (Gilbride & Santos, 2012). This data is reinforced by nearby potash production and the advanced stage of neighbouring lithium projects. The Paradox Basin is believed to contain up to 56 billion tonnes of lithium brines, potentially the largest such resource in US (Source: Anson Fastmarkets Presentation- https://wcsecure.weblink.com.au/pdf/ASN/02823465.pdf ).
The Company’s National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) Potash Exploration Target consists of 500 million to 950 million tonnes of sylvinite (the most important source for the production of potash in North America) grading from 12% to 18% potassium oxide based on elog (eK2O=19% to 29% potassium chloride based on elog (eKCl)). Its Exploration Targets for Lithium and Bromine are 2.1 billion cubic meters (brine volume) grading from 71.6 to 216.3 parts per million lithium; and 2.1 billion cubic meters (brine volume) grading from 3,656 to 4,741 parts per million bromine.**
The Company holds a 100% interest in eleven State of Utah (“SITLA“) mineral and minerals salt leases covering approximately 7,050 acres, 1,094 federal lithium brine claims (BLM Placer Claims) covering 21,150 acres, and 11 federal (BLM) potash prospecting permits covering approximately 25,480 acres. Through these leases, permits and claims the Company has the ability to explore for potash, lithium and potential by-products across the entire Green River Project (approx. 32,530 acres). The Company is authorized to drill a total of 7 drill holes across the Project (pending bonding the recently approved 4 drill holes).
Intrepid Potash, Inc. is America’s largest potash company and only U.S. domestic potash producer and currently produces potash from its nearby Moab Solution Mine, which the Company believes provides strong evidence of stratigraphic continuity within this part of the Paradox Basin (www.intrepidpotash.com). Anson Resources Ltd. has advanced lithium development projects contiguous to the northern boundary of our Green River Project and neighbouring to the south. Anson has a large initial resource, robust definitive feasibility study and has recently completed successful piloting operations through its partnership with Koch Technology Solutions, as well as an offtake agreement with LG Energy Solution. The Anson exploration targets encompass the combined Mississippian Leadville Formation and the Pennsylvanian Paradox Formation brine-bearing clastic layers, which also underlie American Critical Minerals’ entire project area (www.ansonresources.com)*.
In 2022, the U.S. imported approx. 96.5% of its annual potash requirements with domestic producers receiving a higher sales price due to proximity to market (intrepidpotash.com/ August 15, 2024, Investor Presentation). In March 2024, the US Senate introduced a bill to include key fertilizers and potash on the US Department of Interior list of Critical Minerals which already includes lithium, and this process is well advanced with potash being added to the USGS Draft Critical Minerals List. In August 2025. Recent market estimates suggest that the global potash market is over US$50 billion annually and growing at a compound annual growth rate (“CAGR”) of close to 5%. Annual lithium demand is now estimated to be over 1 million tonnes globally and continuing to grow rapidly***.
****Exploration Targets are conceptual in nature and there has been insufficient exploration to define them as Mineral Resources, and, while reasonable potential may exist, it is uncertain whether further exploration will result in the determination of a Mineral Resource under NI 43-101.
Qualified Person
The technical content of this news release has been reviewed and approved by Dean Besserer, P.Geo., the Chief Operations Officer of the Company and a qualified person for the purposes of NI 43-101.
On behalf of the Board of Directors
Simon Clarke, President & CEO
Contact: (604)-551-9665
*American Critical Minerals’ management cautions that results or discoveries on properties in proximity to the American Critical Minerals’ properties may not necessarily be indicative of the presence of mineralization on the Company’s properties.
**A report titled “NI 43-101 Technical Report – Green River Potash and Lithium Project, Grand County, Utah, USA”, prepared by Agapito Associates Inc., and dated October 27, 2025, quantifies the Green River Potash Project’s potash, lithium and bromine exploration potential in the form of NI 43-101 Exploration Targets. The Exploration Target estimate was prepared in accordance with NI 43-101. It should be noted that Exploration Targets are conceptual in nature and there has been insufficient exploration to define them as Mineral Resources, and, while reasonable potential may exist, it is uncertain whether further exploration will result in the determination of a Mineral Resource under NI 43-101. Details of the basis on which the Exploration Targets have been determined is included in the Report. The Exploration Target stated in the Report is not being reported as part of any Mineral Resource or Mineral Reserve. A copy of the report can be accessed on both SEDAR+ (www.sedarplus.ca) and the corporate website for the Company: www.acmineralscorp.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains forward-looking information or forward-looking statements within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: use of proceeds; statements about exploration targets; goals of the Company; magnitude or quality of mineral deposits; anticipated advancement of mineral properties or programs; and future exploration prospects.
Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking statements are based on certain assumptions and analyses made by the Company in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. Forward-looking statements also involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading “Risks and Uncertainties” in the Company’s most recently filed MD&A.
Forward-looking information contained herein are made as of the date of this news release and the Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
